DePuy Weighs HDE Costs; FDA Stresses Data Options Over Statutory Limits
This article was originally published in The Gray Sheet
The Center for Devices & Radiological Health is encouraging greater use of humanitarian device exemptions by inviting manufacturers to submit alternative forms of data to support submissions
You may also be interested in...
The Rare Diseases Working Group of the HHS Secretary's Advisory Committee on Genetic Testing should look at ways to shift testing for rare diseases from research labs to CLIA-certified clinical labs, the committee concluded
FDA is seeking broader use of the humanitarian device exemption program by encouraging dialogue with manufacturers about HDE requirements for patient population and cost
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.